News >

Optimizing Application of Genomic Analyses Critical to Advancing Pancreatic Cancer Care

Gina Columbus @ginacolumbusonc
Published: Wednesday, May 23, 2018

Diane M. Simeone, MD

Diane M. Simeone, MD
Molecular abnormalities, such as BRCA1/2, ATM, CHEK2, and microsatellite instability (MSI), are a handful of subtypes emerging in pancreatic cancer research, but the way these are identified and targeted with treatment still requires further investigation, said Diane M. Simeone, MD.

State of the Science Summit™ on Gastrointestinal Cancers, Simeone, who was also chair of the meeting, discussed the molecular complexities of pancreatic cancer, some of the commonly identified mutations, and ongoing clinical trial efforts that may be game changing for the field.

OncLive: What did you highlight in your presentation on pancreatic cancer?

Simeone: One of the points I wanted to make is that we need to make advances and do things a little differently than we have been to really change outcomes for the disease, which right now is a 9% 5-year survival rate. One of the missing pieces of the puzzle is actually how to best apply genomic analyses to pancreatic cancer. There actually has been a lot of activity, but how to actually best utilize that to help guide patient care has still been a “black box.” 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication